Protocatechuic acid (PCA) is being studied as a possible topical antimicrobial for preoperative skin preparation, particularly for the shoulder, where Cutibacterium acnes can be difficult to address. Early research has examined whether PCA reduces bacteria on human shoulder skin and whether it has antimicrobial activity in a preclinical skin-infection model.
The results are promising enough to justify further investigation, but they do not establish that PCA prevents surgical-site infections in patients. Understanding the difference between reducing bacterial counts and improving surgical outcomes is essential when evaluating this proposed formulation.
Why preoperative shoulder skin preparation is a research challenge
The skin carries bacteria that can be relevant to surgical infection risk. In shoulder surgery, Cutibacterium acnes has received particular attention because it is associated with the skin and pilosebaceous structures around the shoulder. Its presence makes the effectiveness of preoperative skin antisepsis an important research question.
A preparation that reduces bacteria recovered from the skin may be useful, but the laboratory result is only one part of the clinical question. Researchers also need to establish whether an intervention can be used safely and consistently in the surgical setting, how it compares with established preparation methods, and whether it changes patient outcomes.
That distinction matters when assessing any new topical antimicrobial. A reduction in recoverable bacteria does not automatically mean that an intervention prevents deep infection, eliminates every organism in the skin, or improves healing after surgery.
For PCA, the current evidence includes a small human shoulder-skin pilot study and a separate preclinical investigation. These studies address related questions, but they have different designs and limitations.
What is protocatechuic acid?
Protocatechuic acid is a phenolic compound that has been investigated for antimicrobial activity. Research into its potential use for surgical skin antisepsis has included laboratory testing and animal-model work, followed by a pilot study involving human shoulder skin.
The proposed application is topical: researchers are investigating whether a PCA formulation can reduce the bacterial burden at a site relevant to surgery. Formulation details matter because concentration and other ingredients can affect how a topical preparation behaves on skin.
The evidence should be assessed study by study. Findings from a laboratory assay cannot be treated as equivalent to findings from a human skin study, and neither type of evidence alone establishes clinical effectiveness against surgical-site infections.
A patent, if applicable to a formulation, is also separate from clinical evidence. Patent status does not establish that a product is safe, effective, approved for a particular use, or ready for routine clinical adoption.
What the preclinical research found
A 2020 study, “Protocatechuic Acid as a Topical Antimicrobial for Surgical Skin Antisepsis: Preclinical Investigations,” examined PCA’s antimicrobial activity using laboratory testing and a mouse skin-infection model.
In laboratory testing, the researchers compared PCA with several related compounds against organisms relevant to surgical-site infections. PCA showed the broadest antimicrobial spectrum among the compounds tested in that investigation. This result supported further research, but laboratory activity does not by itself predict performance in patients.
The study also evaluated PCA in a mouse model involving intradermal inoculation with C. acnes. The researchers applied PCA at three concentrations over 96 hours. The group treated with the highest concentration, 78 millimolar (mM), had a lower bacterial burden than the untreated group: 5.51 versus 6.65 log colony-forming units per gram. The reported difference was statistically significant (p = 0.0295). The lower concentrations did not show the same effect.
The animal experiment was small, with two mice per group. That limits how confidently the result can be generalized. The model provides preclinical evidence of activity under the conditions tested, not proof that PCA treats human infections or prevents infections after surgery.
The authors identified the need for clinical research. That remains the appropriate interpretation: the study supports further investigation of topical PCA, while leaving important questions about human use unanswered.
What the human shoulder-skin pilot study found
A separate 2020 paper, “Reduced Bacterial Burden of the Skin Surrounding the Shoulder Joint Following Topical Protocatechuic Acid Application: Results of a Pilot Study,” evaluated topical PCA on the shoulders of healthy volunteers.
The study had two phases. In the first, 11 participants received a 10% PCA preparation. In the second, 12 participants received a 17% preparation. The researchers compared the treated shoulder with the opposite shoulder, which was prepared with 70% isopropyl alcohol. PCA was applied for 30 seconds, and skin samples were collected before treatment and 20 minutes afterward.
The reported results suggested that PCA reduced recoverable bacteria under the study conditions. In the 10% group, the reported sterilization rates were 90.9% for aerobic bacteria and 81.8% for anaerobic bacteria. In the 17% group, the reported anaerobic sterilization rate was 83.3%, while the aerobic result showed a trend toward 91.7%. C. acnes was detected after treatment in 18.2% of participants in the 10% group and in none of the participants in the 17% group.
These numbers need context. The study was small, involved healthy volunteers rather than surgical patients, and measured bacterial recovery shortly after application. It did not measure surgical-site infection rates or establish that PCA prevents postoperative infection.
The second phase also included formulation changes, including propylene glycol and peppermint oil, intended to optimize transdermal penetration. Because the formulation changed between phases, the results should not be interpreted as a simple concentration-only comparison between 10% and 17% PCA.
The authors concluded that clinical studies in a surgical shoulder population were warranted to determine whether PCA might reduce shoulder surgical-site infections. That is a measured conclusion, and it should guide how the findings are communicated.
What the evidence does and does not establish
The two studies provide different kinds of evidence. The preclinical study tests antimicrobial activity in laboratory and animal settings. The human pilot study examines short-term bacterial recovery from healthy shoulder skin. Neither establishes whether PCA improves outcomes in people undergoing surgery.
| Research question | What the published studies indicate | What remains unknown |
|---|---|---|
| Does PCA show antimicrobial activity in laboratory testing? | Yes, activity was reported against organisms tested in the preclinical study. | How reliably that activity translates to clinical use. |
| Did PCA reduce bacterial burden in a mouse skin-infection model? | The highest tested concentration reduced C. acnes burden compared with untreated controls. | Whether the effect translates to humans or other clinical settings. |
| Did a human pilot study report lower bacterial recovery after topical PCA? | Yes, the study reported reduced bacterial recovery from healthy shoulder skin. | Whether the approach is effective and safe in surgical patients. |
| Has PCA been shown to prevent surgical-site infections? | The cited studies do not establish this outcome. | Whether a properly designed clinical trial would demonstrate a reduction in infections. |
| Has PCA been shown to accelerate tissue healing? | The two skin-antisepsis studies described here do not establish this claim. | Whether healing outcomes improve in an appropriately designed study. |
This distinction is especially important when discussing claims such as “eradicates resident bacteria,” “destroys biofilms,” or “accelerates healing.” Those claims require direct evidence for the specific effect being described. A reduction in bacteria recovered from the skin is not enough to establish complete eradication, biofilm destruction, or improved tissue repair.
Similarly, evidence that a topical compound reaches or affects skin tissue under experimental conditions does not, by itself, establish the extent of penetration in human patients or show that penetration produces better clinical outcomes.
What should happen before PCA is used routinely?
The next step is clinical evaluation designed to answer questions that the existing studies cannot resolve. A study involving patients undergoing shoulder surgery could assess the formulation in the setting where it is intended to be used, with clearly defined methods and outcomes.
Important questions include:
- Safety and tolerability: Does the preparation cause irritation, sensitivity, or other adverse effects under the intended conditions of use?
- Formulation consistency: Are the concentration, ingredients, application time, and preparation method specified and reproducible?
- Comparator choice: How does PCA perform against an appropriate standard skin-preparation approach?
- Microbiological outcomes: How are bacterial burden and C. acnes measured, and at what time points?
- Clinical outcomes: Does use of the preparation change surgical-site infection rates or other prespecified patient outcomes?
- Study quality: Are the sample size, comparison groups, outcome definitions, and analysis appropriate to the question being tested?
A reduction in bacterial burden may be a useful endpoint during development, but a clinical claim about infection prevention requires evidence that addresses infection outcomes directly. Researchers should also report adverse events and study limitations, including any formulation changes that could affect interpretation.
Clinical research should establish the intended use and conditions of application rather than assuming that results from healthy volunteers or animal models automatically apply to patients undergoing surgery.
How to interpret claims about PCA today
The most defensible summary is that topical PCA is a candidate for further study in preoperative skin antisepsis. Published research has reported reduced bacterial recovery from healthy human shoulder skin and antimicrobial activity in preclinical testing. These findings provide a rationale for additional research, not a basis for claiming that PCA has already been shown to prevent surgical-site infections.
Clinicians and research collaborators assessing a proposed PCA formulation should review the complete study reports, confirm the exact formulation and intended application, and distinguish published findings from hypotheses or planned work. Any statements about patents, regulatory status, compatibility with other antiseptics, biofilm activity, or tissue healing should be supported by the relevant documentation and studies before clinical use.
For teams considering research collaboration, the practical question is not whether early findings sound promising. It is whether the next study can answer a clinically meaningful question with a design that supports a reliable conclusion.
Frequently asked questions
Is protocatechuic acid currently proven to prevent surgical-site infections?
The two 2020 studies discussed here do not prove that topical PCA prevents surgical-site infections. The human study measured short-term bacterial recovery from healthy shoulder skin, while the other study included laboratory and mouse-model experiments. Clinical studies are needed to evaluate infection outcomes in surgical patients.
What bacteria were studied in research on topical PCA?
The preclinical investigation tested PCA against multiple organisms relevant to surgical-site infections and included a mouse skin-infection model using Cutibacterium acnes. The human shoulder-skin pilot also evaluated bacterial recovery, including detection of C. acnes after treatment.
Was PCA tested in patients undergoing shoulder surgery?
The cited human pilot study involved healthy volunteers, not patients undergoing shoulder surgery. Its authors called for clinical studies in a surgical shoulder population to determine whether PCA could reduce surgical-site infections.
Does a higher PCA concentration necessarily work better?
The available pilot results do not establish a simple concentration-response relationship. The study phases differed in formulation as well as concentration, and the study was small. A controlled study designed to compare formulations would be needed to answer that question reliably.
Does PCA eliminate all bacteria from the skin?
The cited studies do not establish complete elimination of all bacteria from skin. They report measured changes in bacterial recovery under specific experimental conditions. Terms such as “eradication” should not be used unless the evidence directly supports that claim.
Has topical PCA been shown to destroy bacterial biofilms?
The two studies summarized here do not establish a clinical biofilm-destruction claim. Any statement about biofilm activity should be tied to a specific experiment or publication that directly tests that outcome.
Has PCA been shown to accelerate wound healing?
The cited skin-antisepsis studies do not establish that topical PCA accelerates tissue healing in surgical patients. A claim about healing would need direct evidence from research designed to measure relevant healing outcomes.
What evidence would help determine whether PCA is ready for clinical use?
Clinical evaluation should assess safety, formulation consistency, performance against an appropriate comparator, microbiological outcomes, and patient outcomes such as surgical-site infections. The study design and reported results need to support the specific intended use.
What to do next
For researchers and potential clinical collaborators, the next steps are to:
- Review the full reports of the 2020 preclinical and human pilot studies.
- Confirm the precise formulation, ingredients, concentration, and application method under consideration.
- Separate established study findings from claims that still need direct evidence.
- Define the safety, microbiological, and clinical outcomes a future study should measure.
- Determine whether the proposed clinical study can evaluate the intended use in the relevant surgical population.
Early research gives a reason to investigate topical PCA further. Whether it becomes a useful option for preoperative skin preparation depends on the results of appropriately designed clinical research.
